TCT 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Shows Low Five-Year Event Rates in BIOFLOW-II RCT and BIOFLOW-III Registry
DENVER, United States and BUELACH, Switzerland, November 2, 2017 - BIOTRONIK's Orsiro1 drug-eluting stent (DES) demonstr…
DENVER, United States and BUELACH, Switzerland, November 2, 2017 - BIOTRONIK's Orsiro1 drug-eluting stent (DES) demonstr…
Data presented during the TCT congress on BIOTRONIK’s Magmaris1 RMS provide further evidence on its continued safety and…
Data presented at the BIOTRONIK-sponsored symposium on the Orsiro1 drug-eluting stent (DES) demonstrate why Orsiro is ga…
BIOTRONIK has announced the start of enrollment of a coronary stent trial aiming at assessing the safety and clinical pe…
BIOTRONIK’s exclusive rate responsive technology, Closed Loop Stimulation (CLS) has shown to reduce fainting in pacemake…
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce…
The European Heart Rhythm Association (EHRA) released the analytical supplement to the 10th EHRA White Book during the E…
Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause mortality and hospitali…
Die Auswertung der CASTLE-AF (Catheter Ablation versus Standard Conventional Treatment in Patients with Left Ventricular…
Cardiology experts will present conclusive results from various BIOTRONIK studies at the European Society of Cardiology’…